Anti-glucagon antibodies

• US 9,657,099 B2
• Filed: 09/15/2015
• Issued: 05/23/2017
• Est. Priority Date: 09/16/2014
• Status: Active Grant

• Current Assignee: Regeneron Pharmaceuticals Incorporated
• Original Assignee: Regeneron Pharmaceuticals Incorporated
• Inventors: Gromada, Jesper, Okamoto, Haruka
• Primary Examiner(s): LANDSMAN, ROBERT S
• Application Number:
  US14/855,274
• Publication Number:
  US 20160075778A1
• Time in Patent Office: 616 Days
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/507 Comprising a combination of two or more separate antibodies
• CPC Class Codes: A61K 2039/54 characterised by the route of administration
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/12 for cataracts
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07K 16/26 against hormones ; against hormone releasing or inhibiting factors
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/76 : Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 : Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: C07K 2317/94 : Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

The present invention provides antibodies that bind to glucagon and methods of using the same. According to certain embodiments, the antibodies of the invention bind human GCG with high affinity. The antibodies of the invention may be fully human antibodies. The antibodies of the invention are useful for the treatment of various diseases or disorders characterized by elevated blood glucose levels, as well as other GCG-related disorders.

Claims

1. An isolated antibody or antigen-binding fragment thereof that specifically binds to glucagon (GCG) and neutralizes GCG activity, wherein the antibody or antigen-binding fragment thereof comprises:

(a) three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) contained within a heavy chain variable region (HCVR) amino acid sequence selected from the group consisting of SEQ ID NOs;

2, 18, 34, 50, 66, 82, 98, 114, 130 and 146; and

(b) three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within a light chain variable region (LCVR) amino acid sequence selected from the group consisting of SEQ ID NOs;

10, 26, 42, 58, 74, 90, 106, 122, 138 and 154.

2. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment comprises an HCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs:

2, 18, 34, 50, 66, 82, 98, 114, 130 and 146; and

a LCVR having an amino acid sequence selected from the group consisting of SEQ ID NOs;

10, 26, 42, 58, 74, 90, 106, 122, 138 and 154.

3. The isolated antibody or antigen-binding fragment thereof of claim 2, comprising a HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs:

2/10;

18/26;

34/42;

50/58;

66/74;

82/90;

98/106;

114/122;

130/138 and 146/154.

4. The isolated antibody or antigen-binding fragment thereof of claim 1, comprising:

(a) a HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs;

4, 20, 36, 52, 68, 84, 100, 116, 132 and 148;

(b) a HCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs;

6, 22, 38, 54, 70, 86, 102, 118, 134 and 150;

(c) a HCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs;

8, 24, 40, 56, 72, 88, 104, 120, 136 and 152;

(d) a LCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs;

12, 28, 44, 60, 76, 92, 108, 124, 140 and 156;

(e) a LCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs;

14, 30, 46, 62, 78, 94, 110, 126, 142, and 158; and

(f) a LCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs;

16, 32, 48, 64, 80, 96, 112, 128, 144 and 160.

5. The isolated antibody or antigen-binding fragment thereof of claim 1, comprising:

(a) a HCDR1 domain comprising the amino acid sequence of SEQ ID NO;

20;

(b) a HCDR2 domain comprising the amino acid sequence of SEQ ID NO;

22;

(c) a HCDR3 domain comprising the amino acid sequence of SEQ ID NO;

24;

(d) a LCDR1 domain comprising the amino acid sequence of SEQ ID NO;

28;

(e) a LCDR2 domain comprising the amino acid sequence of SEQ ID NO;

30; and

(f) a LCDR3 domain comprising the amino acid sequence of SEQ ID NO;

32.

6. The isolated antibody or antigen-binding fragment thereof of claim 1, comprising:

(a) a HCDR1 domain comprising the amino acid sequence of SEQ ID NO;

36;

(b) a HCDR2 domain comprising the amino acid sequence of SEQ ID NO;

38;

(c) a HCDR3 domain comprising the amino acid sequence of SEQ ID NO;

40;

(d) a LCDR1 domain comprising the amino acid sequence of SEQ ID NO;

44;

(e) a LCDR2 domain comprising the amino acid sequence of SEQ ID NO;

46; and

(f) a LCDR3 domain comprising the amino acid sequence of SEQ ID NO;

48.

7. An isolated monoclonal antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or fragment thereof exhibits one or more of the following characteristics:

(a) is a fully human monoclonal antibody;

(b) binds human GCG at 25°

C. with a K_D ranging from about 50 pM to about 750 pM and less than from about 300 pM to about 5 nM at 37°

C. as measured by surface plasmon resonance;

(c) lowers blood glucose levels by at least about 10% when administered to a mammal as a single dose, or as multiple doses of less than about 40 mg/kg;

or

(d) inhibits GCG-mediated activation of cells expressing human glucagon receptor (GCGR) with an IC₅₀ ranging from about 7 pM to about 950 pM.

8. The isolated antibody or antigen-binding fragment thereof of claim 7, wherein the antibody lowers blood glucose levels by about 10% to about 31% when administered to a mammal as a single dose, or as multiple doses ranging from about 3 mg/kg to about 30 mg/kg.

9. The isolated antibody or antigen-binding fragment thereof of claim 7, wherein the antibody or an antigen-binding fragment thereof reduces blood glucose levels in a mammal when administered subcutaneously, intravenously, or intramuscularly.

10. The isolated antibody or antigen-binding fragment thereof of claim 7, wherein the antibody or an antigen-binding fragment thereof reduces blood glucose levels in a mammal suffering from a condition or disease associated with, or characterized in part by high blood glucose levels.

11. The isolated antibody or antigen-binding fragment thereof of claim 10, wherein the condition or disease associated with, or characterized in part by high blood glucose levels is selected from the group consisting of diabetes, impaired glucose tolerance, obesity, hyperglycemia, hyperglycemic hyperosmolar syndrome, perioperative hyperglycemia, hyperglycemia in the intensive care unit patient, hyperinsulinemia, the metabolic syndrome, insulin resistance syndrome and impaired fasting glucose.

12. A pharmaceutical composition comprising a therapeutically effective amount of an isolated antibody or antigen-binding fragment thereof that binds to GCG according to claim 1 and a pharmaceutically acceptable carrier or diluent.

13. An isolated antibody or antigen-binding fragment thereof that competes for specific binding to GCG with an antibody or antigen-binding fragment comprising heavy and light chain sequence pairs selected from the group consisting of SEQ ID NOs:

2/10;

18/26;

34/42;

50/58;

66/74;

82/90;

98/106;

114/122;

130/138 and 146/154.

14. An isolated antibody or antigen-binding fragment thereof that binds to the same epitope on GCG as a reference antibody comprising an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs:

2/10;

18/26;

34/42;

50/58;

66/74;

82/90;

98/106;

114/122;

130/138 and 146/154.